Publications by authors named "Marina Duller"
Article Synopsis
- COPD exacerbations lead to worse health outcomes and higher healthcare costs, prompting the development of targeted lung denervation (TLD) to disrupt unhealthy nerve activity in the lungs.
- The AIRFLOW-2 study evaluated the safety and effectiveness of TLD combined with standard therapy versus a sham procedure over two years in patients with moderate-to-severe COPD.
- Results showed that TLD significantly delayed severe COPD flare-ups and maintained stable lung function and quality of life over the study period.
Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion. To determine the safety and impact of TLD on respiratory adverse events. We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale score, ≥2; or COPD Assessment Test score, ≥10) COPD (FEV, 30-60% predicted).
View Article and Find Full Text PDF